Mainz Biomed BV

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition ReconAAsense designed to evaluate gold standard at-home colorectal cancer screening test and is on track to commence enrollment in mid-2024 Expanded international commercialization of ColoAlert® in major European markets and Israel BERKELEY, Calif. and MAINZ, Germany, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Provides Year-End Corporate Review 2023

Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82% Results Exceed those from the Company's European ColoFuture Clinical Study of the Same Design ColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial is On Track to Commence Enrollment in Mid-2024 BERKELEY, Calif. and MAINZ, Germany, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80% BERKELEY, Calif. and MAINZ, Germany, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

BERKELEY, Calif. and MAINZ, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagnostic company shared results from a colorectal cancer screening test campaign. The company held this screening test campaign with the help of partner Zöller-Kipper GmbH.

Why Is Mainz Biomed (MYNZ) Stock Moving Today?

BERKELEY, Calif. and MAINZ, Germany, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced positive interim results from its CRC screening campaign through its BGM (“betriebliches Gesundheitsmanagement”) partnership with Zöller-Kipper GmbH, part of the Zöller group with more than 2,600 employees.

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert ® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CRC Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 80% BERKELEY, Calif. and MAINZ, Germany, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week.

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

BERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed's flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - with strategic partner Bioclinica, a national leader in the Romanian healthcare sector.

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group's 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept.

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023 in New York City.

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense)

Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4

Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference

Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland

News for Mainz Biomed BV Stock (MYNZ)